Innovent climbs most in a week on new drug application for gastric cancer

Innovent Biologics

05/06/2026 03:26

** Shares of Innovent Biologics 1801.HK climb 4.4% to HK$79.8, on course for the biggest one-day pct gain since May 29
** Stock touches the highest level since June 2, on track to snap four straight declining sessions; third biggest pct gainer in benchmark Hang Seng Index .HSI, which slips 0.5%
** Innovent says new drug application of arcotatug tavatecan has been accepted by China's National Medical Products Administration (NMPA) for advanced refractory gastric cancer
** International multi-center phase 3 clinical study of arcotatug tavatecan has completed the per-protocol first interim analysis and reached the primary endpoint, demonstrating excellent efficacy and a tolerable safety profile in the treatment of advanced gastric cancer - Co 
** YTD, stock up 2.7%, while Hang Seng Biotech Index .HSBIO down 11.1%



 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))